AX9 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Akebia Therapeutics Inc

Watchlist Manager

Watchlist

Price: 1.2675 EUR 7.78%

Market Cap: €422.1m

A	Akebia Therapeutics Inc SWB:AX9	US
D	Deutsche Telekom AG XBER:DTE	DE
S	Starbucks Corp F:SRB	US
T	Tencent Holdings Ltd XHAM:NNND	CN
	MLP SE F:MLP	DE
E	Ence Energia y Celulosa SA SWB:ENCA	ES

Profitability Summary

Akebia Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

83%

Strong 3Y Average Gross Margin

83%

Declining Gross Margin

85% > 83%

Healthy Operating Margin

11%

Negative 3Y Average Operating Margin

-15%

Operating Margin is Increasing

-13% > 11%

Negative Net Margin

-2%

Negative 3Y Average Net Margin

-25%

Net Margin is Increasing

-23% > -2%

Exceptional Free Cash Flow Margin

25%

Negative 3Y Average Free Cash Flow Margin

-13%

Free Cash Flow Margin is Increasing

-26% > 25%

Exceptional ROE

64%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-12%

ROIC is Increasing

-12% > 23%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.